secwatch.observer — SEC 8-K summary
======================================

Issuer:     CUMBERLAND PHARMACEUTICALS INC (CPIX)
CIK:        0001087294
Form:       8-K
Filed at:   2023-05-09T23:59:59+00:00
Accession:  0001628280-23-016892
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cumberland Pharma Q1 net revenue $9.2M, adj. EPS $0.11; expects Caldolor Medicare boost under NOPAIN Act
--------------------------------------------------------------------------------

- Q1 2023 net revenues of $9.2M; net income of $0.2M ($0.01 EPS); adjusted earnings of $1.7M ($0.11 EPS).
- Product revenue: Kristalose $4.3M, Sancuso $1.9M, Vibativ $1.8M, Caldolor $0.9M.
- Caldolor expected to qualify for separate Medicare reimbursement under the NOPAIN Act, enacted April 2023.
- FDA granted barrier-to-innovation waiver, refunding nearly $2M in RediTrex prescription drug program fees.
- Balance sheet: $89M assets, $16M cash, $53M liabilities (including $16M drawn on revolver), $36M equity.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1087294/000162828023016892/0001628280-23-016892-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1087294/000162828023016892/cpix-20230509.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-016892

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer